TG Therapeutics | TGTX - Debt


TG Therapeutics reported $753.56M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 57.32B 2.72B Mar/2026
Ardelyx USD 208.26M 653K Mar/2026
Arrowhead Research USD 989.46M 676.69M Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 8.09B 1.53B Jun/2026
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Curis USD 0 0 Jun/2022
Gilead Sciences USD 22.17B 2.76B Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
TG Therapeutics USD 753.56M 499.85M Mar/2026
Verastem USD 66.79M 26.7M Sep/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026